We are live on ! Find out more
EHI

Eagle Health Investments Portfolio holdings

AUM $603M
1-Year Est. Return 111.06%
This Fund
S&P 500
This Quarter Est. Return
-10.28%
1 Year Est. Return
+111.06%
3 Year Est. Return
+240.87%
5 Year Est. Return
+290.92%
10 Year Est. Return
AUM
$454M
AUM Growth
-$81M
Cap. Flow
-$13M
Cap. Flow %
-2.86%
Top 10 Hldgs %
72.29%
Holding
27
New
Increased
7
Reduced
5
Closed
4

Top Buys

Rank Stock Value
1
TMDX icon
Transmedics
TMDX
+$13.1M
2
DXCM icon
DexCom
DXCM
+$12.8M
3
LNTH icon
Lantheus
LNTH
+$12M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$8.69M
5
INSP icon
Inspire Medical Systems
INSP
+$5.14M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CTLT
26
DELISTED
CATALENT, INC.
CTLT
-459,621
Closed -$19.9M
CANO
27
DELISTED
Cano Health, Inc.
CANO
-42,909
Closed -$5.96M

Similar funds

Eagle Health Investments's Q3 2023 Portfolio in Review

As of Q3 2023, Eagle Health Investments held 27 positions worth $454M, down 15% from $535M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Eagle Health Investments's Q3 2023 filing shows 7 increased, 5 reduced and 4 closed positions. The largest sale was CATALENT, INC., an estimated $19.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Eagle Health Investments added most to Transmedics in Q3 2023, an estimated $13.1M increase.
  • Eagle Health Investments's biggest Q3 2023 reduction was Intuitive Surgical, cutting an estimated $13.7M.
  • Eagle Health Investments fully exited CATALENT, INC. in Q3 2023, selling an estimated $19.9M.
  • Eagle Health Investments's ten largest holdings make up 72% of its $454M portfolio in Q3 2023.
  • Eagle Health Investments opened 0 new positions and closed 4 in Q3 2023.
  • Eagle Health Investments's portfolio value fell 15% quarter-over-quarter to $454M.

Based on Eagle Health Investments's 13F filing for Q3 2023, filed 27 Oct 2023.